Journal
ONCOLOGY LETTERS
Volume 22, Issue 3, Pages -Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ol.2021.12935
Keywords
RNA-binding protein 24; tumor protein 63; beta-catenin; nuclear translocation; drug resistance; tumor suppressor
Categories
Funding
- Basic Science Research Program through the National Research Foundation of Korea - Ministry of Science, ICT & Future Planning [NRF-2019R1I1A1A01061167, 2019R1A5A2026045, NRF-2017R1E1A1A01074733, NRF-2017M3A9B6061509, NRF-2017M3C9A6047620]
- National Research Foundation of Korea [2017M3C9A6047620, 2019R1A5A2026045] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
RBM24 functions as a tumor suppressor in liver cancer cells by inhibiting nuclear translocation of beta-catenin and tumor protein 63 expression, as well as suppressing sphere formation in liver cancer cells. It is hypothesized to be a potential novel therapeutic target for liver cancer treatment.
RNA-binding protein 24 (RBM24) has been shown to play tumor-suppressive functions in various types of cancer. The present study aimed to investigate the role of RBM24 in liver cancers and its downstream mechanisms. The present study demonstrated that RBM24 functioned as a tumor suppressor in liver cancer cells, and inhibited nuclear translocation of beta-catenin and tumor protein 63 expression by immunocytochemistry. In addition, RBM24 could suppress sphere formation in a multicellular tumor spheroid model of liver cancer cells. In conclusion, it is hypothesized that RBM24 is a tumor suppressor of liver cancer cells, which could be a potential novel therapeutic target for treatment of patients with liver cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
